NUVL Stock Forecast 2025-2026
Distance to NUVL Price Targets
NUVL Price Momentum
10 Quality Stocks Worth Considering Now
Researching Nuvalent (NUVL) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on NUVL and similar high-potential opportunities.
Latest NUVL Stock Price Targets & Analyst Predictions
Based on our analysis of 14 Wall Street analysts, NUVL has a bullish consensus with a median price target of $110.00 (ranging from $100.00 to $137.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $71.64, the median forecast implies a 53.5% upside. This outlook is supported by 11 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by David Dai at UBS, suggesting a 39.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NUVL Analyst Ratings
NUVL Price Target Range
Latest NUVL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NUVL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 14, 2025 | UBS | David Dai | Buy | Upgrade | $100.00 |
| Mar 3, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $110.00 |
| Jan 17, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $110.00 |
| Dec 30, 2024 | HC Wainwright & Co. | Buy | Initiates | $0.00 | |
| Nov 13, 2024 | BMO Capital | Etzer Darout | Outperform | Maintains | $134.00 |
| Oct 24, 2024 | UBS | David Dai | Neutral | Initiates | $100.00 |
| Oct 4, 2024 | JP Morgan | Anupam Rama | Overweight | Maintains | $125.00 |
| Sep 16, 2024 | Guggenheim | Kelsey Goodwin | Buy | Maintains | $105.00 |
| Sep 16, 2024 | Wedbush | David Nierengarten | Outperform | Maintains | $115.00 |
| Sep 16, 2024 | Stifel | Bradley Canino | Buy | Maintains | $135.00 |
| Sep 16, 2024 | BMO Capital | Etzer Darout | Outperform | Maintains | $132.00 |
| Sep 9, 2024 | Wedbush | David Nierengarten | Outperform | Reiterates | $99.00 |
| Sep 4, 2024 | JP Morgan | Anupam Rama | Overweight | Maintains | $100.00 |
| Aug 29, 2024 | Barclays | Carter Gould | Overweight | Initiates | $100.00 |
| Jul 10, 2024 | Stifel | Bradley Canino | Buy | Maintains | $115.00 |
| May 17, 2024 | Wedbush | David Nierengarten | Outperform | Reiterates | $99.00 |
| Apr 17, 2024 | Jefferies | Roger Song | Buy | Initiates | $97.00 |
| Apr 1, 2024 | Leerink Partners | Andrew Berens | Outperform | Upgrade | $110.00 |
| Mar 6, 2024 | JP Morgan | Anupam Rama | Overweight | Maintains | $98.00 |
| Feb 28, 2024 | Guggenheim | Kelsey Goodwin | Buy | Assumes | $99.00 |
Nuvalent Inc. (NUVL) Competitors
The following stocks are similar to Nuvalent based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Nuvalent Inc. (NUVL) Financial Data
Nuvalent Inc. has a market capitalization of $5.13B with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -29.5%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Nuvalent Inc. (NUVL) Business Model
About Nuvalent Inc.
Develops innovative small molecule cancer therapies.
Nuvalent Inc. focuses on oncology research and development, creating targeted therapies for cancer patients facing resistance mutations and treatment side effects. The company generates revenue through partnerships and collaborations with research institutions, advancing its drug pipeline and potentially licensing its therapies to larger pharmaceutical companies.
With a commitment to addressing significant gaps in cancer treatment, Nuvalent's innovative approach positions it as a key player in the biopharmaceutical industry. Founded to enhance patient care, its research initiatives aim to improve the quality of life for cancer patients around the world.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
142
CEO
Dr. James R. Porter Ph.D.
Country
United States
IPO Year
2021
Website
www.nuvalent.comNuvalent Inc. (NUVL) Latest News & Analysis
Nuvalent, Inc. (Nasdaq: NUVL) announced the appointment of James Porter, Ph.D., as part of its focus on targeted cancer therapies.
Nuvalent's focus on targeted cancer therapies and leadership announcements can influence stock performance, signaling potential advancements in drug development and market competitiveness.
Nuvalent, Inc. will present preclinical data on its ALK inhibitor neladalkib and ROS1 inhibitor zidesamtinib at the AACR Annual Meeting 2025 from April 25-30 in Chicago.
Nuvalent's upcoming presentations on its targeted cancer therapies may signal advancements in drug efficacy, influencing investor confidence and potential stock performance.
Nuvalent, Inc. (Nasdaq: NUVL) announced the appointment of James Porter, Ph.D., as part of its focus on developing targeted cancer therapies.
Nuvalent's announcement of leadership changes may signal strategic shifts or advancements in their cancer therapies, impacting future performance and investor sentiment.
Nuvalent, Inc. plans to submit an NDA in mid-2025 for zidesamtinib targeting TKI pre-treated ROS1-positive NSCLC, with pivotal data expected in 2025. A Phase 3 trial for neladalkib is also set to start.
Nuvalent's upcoming drug approvals and trials for targeted cancer therapies could significantly impact their valuation and market position, influencing investor sentiment and stock performance.
Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones
3 months agoThe company plans to submit an NDA for zidesamtinib by mid-2024 for ROS1-positive NSCLC, with pivotal data expected in 2025. Neladalkib data is anticipated by year-end 2025.
The expedited NDA submission and upcoming pivotal data for zidesamtinib and neladalkib suggest potential revenue growth and market opportunities, impacting stock valuation and investor sentiment.
Nuvalent: A Logical Acquisition Target
3 months agoNuvalent's NVL-655 and Zidesamtinib demonstrate strong potential for NSCLC with positive trial results and FDA designations. Healthy cash runway until 2028 positions it as a potential M&A target.
Nuvalent's promising drug trials and strong financial health position it as an attractive M&A target, while potential regulatory and competitive risks could impact future performance.
Frequently Asked Questions About NUVL Stock
What is Nuvalent Inc.'s (NUVL) stock forecast for 2025?
Based on our analysis of 14 Wall Street analysts, Nuvalent Inc. (NUVL) has a median price target of $110.00. The highest price target is $137.00 and the lowest is $100.00.
Is NUVL stock a good investment in 2025?
According to current analyst ratings, NUVL has 11 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $71.64. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NUVL stock?
Wall Street analysts predict NUVL stock could reach $110.00 in the next 12 months. This represents a 53.5% increase from the current price of $71.64. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Nuvalent Inc.'s business model?
Nuvalent Inc. focuses on oncology research and development, creating targeted therapies for cancer patients facing resistance mutations and treatment side effects. The company generates revenue through partnerships and collaborations with research institutions, advancing its drug pipeline and potentially licensing its therapies to larger pharmaceutical companies.
What is the highest forecasted price for NUVL Nuvalent Inc.?
The highest price target for NUVL is $137.00 from at , which represents a 91.2% increase from the current price of $71.64.
What is the lowest forecasted price for NUVL Nuvalent Inc.?
The lowest price target for NUVL is $100.00 from David Dai at UBS, which represents a 39.6% increase from the current price of $71.64.
What is the overall NUVL consensus from analysts for Nuvalent Inc.?
The overall analyst consensus for NUVL is bullish. Out of 14 Wall Street analysts, 11 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $110.00.
How accurate are NUVL stock price projections?
Stock price projections, including those for Nuvalent Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.